Effect of Treatment of Diabetic Foot Ulcers With Topic 8% 1-phenyl-5-methyl-2-[1h]-Pyridone (Pirfenidone) Combined With Modified Disulfur Diallyl Oxide (Odd-m) in Gel.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Ulcer size
研究概览
简要总结
Pirfenidone is a synthetic molecule, which acts as a potent modulator of the effect of various cytokines (TNF-α, transforming growth factor-β, platelet derived growth factor and vascular endothelial growth factor, among others) that possesses anti-inflammatory and anti-fibrinolytic properties.
The aim of this study is to compare the effect of topic treatment with pirfenidone compared to conventional treatment in chronic diabetic foot ulcers.
The hypothesis is that treatment with topic pirfenidone in chronic diabetic foot ulcers (Wagner 1 to 2) reduces the ulcer size and shortens the healing time compared to conventional treatment. This is a randomized, controlled and crossover study. Patients will be randomly assigned to conventional treatment or topic pirfenidone for eight weeks. At the end of this period they will change groups. Each week ulcers will be for size, depth, length and evidence of infection. The ulcers will have proper debridement in the conventional treatment group and debridement plus topical pirfenidone application in the pirfenidone group. Subjects will be instructed to do daily ulcer cleansing and for those in the topical pirfenidone group, in addition to cleansing they will be instructed to apply the gel twice a day.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women
- •Type 1 or 2 diabetes
- •Age ≥ 18 years
- •Wagner 1 or 2 diabetic foot ulcer
- •Diabetic ulcer for more than 8 weeks duration
- •Willing to participate in the study with signed informed consent
排除标准
- •Ankle/brachial index < 0.4 (critic ischemia)
- •Use topical or systemic antibiotics
- •Inability to attend to the weekly evaluations
- •Inability to do daily ulcer cleansing
- •Autoimmune diseases
- •Active pharmacologic topical or systemic ulcer treatment
- •Treatment with immunosuppressors such as steroids, radiotherapy, chemotherapy
- •Pregnancy or lactation
研究组 & 干预措施
Conventional treatment
Weekly ulcer debridement and daily cleansing
干预措施: Debridement (Procedure)
Pirfenidone
Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application
干预措施: Pirfenidone (Drug)
Pirfenidone
Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application
干预措施: Debridement (Procedure)
结局指标
主要结局
Ulcer size
时间窗: 16 weeks
次要结局
未报告次要终点
